Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Zoledronate Osteosarcoma	University of Florida	P1/2	CCC (53)
[11c]cppc Amyotrophic Lateral Sclerosis	Johns Hopkins University	P1/2	CCC (52)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- Lymphoid Malignancies	National Cancer Institute (NCI)	P1/2	CCC (52)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Mood Disorder	King's College London	P1/2	CCC (52)
3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE Renal Cell Carcinoma	Kidney Cancer Research Bureau	P1/2	CCC (52)
5-azacytidine B-Cell Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (52)
68ga-nym005 Nonpapillary Renal Cell Carcinoma	Norroy Bioscience Co., LTD	P1/2	CCC (52)
Abemaciclib Metastatic Colorectal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Acetylsalicylic Acid Metabolic Dysfunction-Associated Steatotic Liver Disease	Galala University	P1/2	CCC (52)
Adagrasib KRAS Activating Mutation	Verastem, Inc.	P1/2	CCC (52)
Adalimumab Mucopolysaccharidosis Type 1	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	P1/2	CCC (52)
Adalimumab Mucopolysaccharidosis Type 2	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	P1/2	CCC (52)
Adalimumab Mucopolysaccharidosis Type 6	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	P1/2	CCC (52)
Adx-629 Sjogren-Larsson Syndrome	University of Nebraska	P1/2	CCC (52)
aj201 Kennedy Disease	AnnJi Pharmaceutical Co., Ltd.	P1/2	CCC (52)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Plasma Cell Myeloma	David Wald	P1/2	CCC (52)
Anti-Cd19/Cd22 Car-T Cells Follicular Lymphoma	First Affiliated Hospital Xi'an Jiaotong University	P1/2	CCC (52)
Anti-Gprc5D Car-T Cells Plasma Cell Myeloma	XuYan	P1/2	CCC (52)
Anvumetostat MTAP-null Solid Tumors	Amgen	P1/2	CCC (52)
APG 115 High-risk Myelodysplastic Syndrome	Ascentage Pharma Group Inc.	P1/2	CCC (52)
Ari-0001 Refractory Chronic Lymphocytic Leukemia	GUSTAVO SALGUERO	P1/2	CCC (52)
Asidna Ovarian Carcinoma	Valerio Therapeutics	P1/2	CCC (52)
Atezolizumab Kidney Neoplasm	Cancer Research UK	P1/2	CCC (52)
Avapritinib Relapsed Solid Neoplasm	Blueprint Medicines Corporation	P1/2	CCC (52)
Avapritinib Solid Tumor, Unspecified, Child	Blueprint Medicines Corporation	P1/2	CCC (52)

Showing 476 to 500 of 8,400 assets

PreviousPage 20 of 336Next